SGLT2 inhibitor use tied to fewer atrial arrhythmias
Empagliflozin a winner in challenging arena of stabilized acute HF
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of...
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
Opioid-induced adrenal insufficiency for the hospitalist
Opioid-induced adrenal insufficiency is an underrecognized cause of central adrenal insufficiency.
Age, C-reactive protein predict COVID-19 death in diabetes
“This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and...
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes....
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say...
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
At 18 months, much still unknown about diabetes and COVID-19
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its...